Recent News

• 04.17.2025 - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
• 11.20.2024 - Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
• 11.15.2024 - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
• 11.15.2024 - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
• 08.17.2024 - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• 08.17.2024 - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Recent Filings

• 04.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.15.2024 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.15.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]